April 11, 2019 11:06 AM EDT
News Briefing

Cam­brex com­pletes $24M API man­u­fac­tur­ing fa­cil­i­ty; Twist and LakePhar­ma part­ner on an­ti­body con­tract work

John Carroll

Editor & Founder

→ Cam­brex Cor­po­ra­tion $CBM com­plet­ed its $24 mil­lion API (HPA­PI) man­u­fac­tur­ing fa­cil­i­ty at its site in Charles City, IA. The fa­cil­i­ty is un­der­go­ing val­i­da­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Q&A with Obe­si­ty So­ci­ety’s CEO as the field pre­pares for next-gen meds

Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

A service from the Financial Times